Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
SLRN.US
id: 877

Acelyrin (SLRN) Clinical Trial Case

C.D. California
Court
2:23-cv-09672
Case number
04 May 2023
Class period Start
11 Sept 2023
Class period End
15 Jan 2024
Lead Plaintiff motion deadline
  • Acelyrin allegedly exaggerated one of its main product effectiveness.
  • On September 13, 2023, the truth came out, leading to a 16% $SLRN fall.
Acelyrin went public in May, 2023, selling 30 million shares at $18.00 each.

In September, Acelyrin revealed disappointing results for izokibep (one of its main drugs) in a clinical trial.

This news caused $SLRN fall by 16% and $203M loss of market cap, damaging shareholders.

Given all this information, investors have reason to suspect that Acelyrin misled about izokibep's success, leading to an overestimation of its business prospects after going public.
Case Status
Lead Plaintiff Appointed
Alleged Offence
Mismanagement
Misleading Statements
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
13 September 2023
Filing date
15 November 2023
Lead Plaintiff Deadline
15 January 2024
Judge
Maria A Audero
Collecting participants…